

1 **Pre-pandemic SARS-CoV-2 potential natural immunity among population**  
2 **of the Democratic Republic of Congo**

3

4 **Authors**

5 Marc SOURIS<sup>1</sup>, Léon TSHILOLO<sup>2,3</sup>, Daniel PARZY<sup>4</sup>, Rachel KAMGAING<sup>5</sup>, Destin  
6 MBONGI<sup>3</sup>, Baltazar PHOBA<sup>3</sup>, Marie-Anasthasie TSHILOLO<sup>3</sup>, René MBUNGU<sup>3</sup>, Pierre  
7 MORAND<sup>6</sup>, Jean-Paul GONZALEZ<sup>7</sup>

8 **Affiliations**

9 <sup>1</sup>UMR Unité des Virus Émergents (UVE Aix-Marseille Univ-IRD 190-Inserm 1207),  
10 Marseille 13005 France

11 <sup>2</sup>Centre Hospitalier Mère-Enfant Monkole, Kinshasa, RD Congo

12 <sup>3</sup>Centre de Formation et d'Appui Sanitaire (CEFA), Mont-Ngafula, Kinshasa. BP 817 - RD  
13 Congo

14 <sup>4</sup>Defideva/Altadeva – Biological Lab, Luminy Biotech, Marseille 13009 France

15 <sup>5</sup>Centre International de Reference Chantal Biya (CIRCB), Yaoundé, Cameroon

16 <sup>6</sup>UMI « Résiliences » (IRD-CIRES), Bondy 93143 France

17 <sup>7</sup>School of Medicine, Georgetown University, Department of Microbiology & Immunology,  
18 Washington, DC 20057 USA. Centaurus Biotech LLC, Vienna, VA, USA

19 **Corresponding author**

20 Marc SOURIS, [marc.souris@ird.fr](mailto:marc.souris@ird.fr)

21 **Keywords**

22 SARS-CoV-2, Natural immunity, antibody, COVID-19, DRC

23 **Acknowledgements**

24 INNOBIOCHIPS Company, for sharing original data and analytical process.

25 **Funding**

26 “Fond de crise COVID-19”, IRD (Institut de Recherche pour le Développement), Marseille,  
27 France

28 **ABSTRACT**

29 More than a year after the emergence of COVID-19, significant regional differences in terms  
30 of morbidity persist, showing lower incidence rates in sub-Saharan Africa, Southeast Asia,  
31 and Oceania. Like SARS-CoV-1 and MERS viruses, SARS-CoV-2 is monophyletically  
32 positioned with parental species of chiropteran coronavirus. Furthermore, we observe that the  
33 spatial distribution of several targeted bat species (i.e., Coronavirus species hosts) overlaps  
34 the distribution of countries with low COVID-19 incidence.

35 The work presented here aims to test the presence of natural immunity among population  
36 with a low COVID-19 prevalence, potentially due to a previous exposure to coronavirus  
37 antigens of a virus close related to SARS-CoV-2. To identify such pre-existing immunity, an  
38 ELISA serological test was used to detect IgG antibodies targeting main SARS-CoV-2  
39 proteins including: the N-protein, the Spike 1 (S1) protein, the receptor binding domain  
40 (RBD) of the S1 protein, the N-terminal domain (NTD) of the S1 protein, and the S2 protein.

41 A total of 574 sera samples collected before 2019 in the population of the Democratic  
42 Republic of Congo (DRC) were tested). 189 control sera from blood donors in France were  
43 used as control samples.


44 The results showed a statistically significant difference between the DRC samples and control  
45 samples for all antigens (N, S1, S2, NTD) except for RBD. The percentage of positive  
46 samples presenting reactive antibodies for S1 antigen was respectively of 19.2% for RDC  
47 versus 2.11% for the control, and of 9.3% versus 1.6% for the S2 antigen.

48 In conclusion, our data showed that the study population has been potentially exposed to a  
49 SARS-CoV-2-like virus antigen before the pandemic in the Central African sub-region.  
50 Therefore, it is quite legitimate to think that this prior immunity may be protective and  
51 responsible for the observed low prevalence of COVID-19. Moreover, we can assume that  
52 this not yet identified SARS-CoV-2-like could be associated to a chiropteran species in close  
53 contact with the studied population. In order to confirm the presence of SARS-CoV-2-like  
54 virus antibodies and ultimately identify the neutralizing potential for the detected antibodies,  
55 our study is underway in other African and Asian countries, where the COVID-19 prevalence  
56 is limited.

57

58 **INTRODUCTION**

59 **COVID-19 morbidity in the world.** More than a year after the emergence of COVID-19,  
60 significant regional differences persist, showing the lowest incidence rates in sub-Saharan  
61 Africa, Southeast Asia, and Oceania. This trend was observed at the onset of the epidemic  
62 and has been confirmed during subsequent waves [WHO 2021].




63  
64 Fig. 1. COVID-19 incidence in the World, as for April 19, 2021 (Source: WHO Coronavirus  
65 Disease Dashboard, 2021)

66 Many hypotheses have been proposed to explain this situation, including among others: the  
67 morbidity and mortality counts are likely to be underestimated in some low- and middle-  
68 income countries due to limited epidemiological surveillance and/or public health screening  
69 activity; the population of sub-Saharan Africa is younger, with only 2.3% of the population  
70 over 65 years of age (whereas people over 65 years of age account for more than three-  
71 quarters of the deaths related to COVID-19 in Europe, where this population represents more  
72 than 20% of the population); more rural living conditions may reduce the spread of the  
73 disease; climatic and environmental conditions unfavorable to the virus and its spread;  
74 and/or, the presence of a natural immunity innate (nonspecific) or secondary due to previous  
75 contact with a coronavirus close to SARS-CoV-2 and sharing common antigenic profiles.  
76 The present work aims to test this last hypothesis.

77 **Coronavirus and bats.** SARS-CoV-2 virus pertains to the Betacoronavirus genus, which  
78 includes numerous virus species of Chiropterans. Chiropteran species are also supposed hosts

79 of coronaviruses close to the original strain of SARS-CoV-2 isolated in China [Zhou 2020].  
80 SARS-CoV-1 and MERS viruses are also monophyletically placed with chiropteran  
81 coronavirus parental species [Li 2005]. Moreover, in Cambodia and Myanmar, a virus closely  
82 related to SARS-CoV-2 was isolated from bat samples (*Rhinolophus Shameli*) collected in  
83 2010 [Mallaparty 2020] [Hul 2021] [Hu 2017]. Globally, it can be observed that the spatial  
84 distribution of fruit bats matches the spatial distribution of countries with lower symptomatic  
85 circulation of COVID-19, especially in rural populations (Fig. 2). Ecology and behavior of  
86 bats, especially fruit bats (e.g.: mass frequentation of fruit orchards, roosting trees close to  
87 dwelling) may have favored the direct or indirect contact with humans. Such type of  
88 antigenic relationship and acquisition of natural immunity without morbidity, have already  
89 been observed with several viruses, including filoviruses and flaviviruses [Gonzalez 2000]  
90 [Becquart 2010] [Dos Santos Franco 2019].



91

92 Fig. 2: Fruit bats geographic distribution (Source: J. Kingdom, Mammals of Africa, Vol. 4).

93 **SARS-CoV-2 Antigenic structure.** The long genome of Coronaviruses mainly encodes four  
94 major structural proteins: spike or S; envelope (E); membrane (M); nucleocapsid (N). The  
95 spike-shaped transmembrane glycoprotein (S) on the surface of the virus plays an essential  
96 role in virus attachment, fusion, entry, and transmission. It comprises two functional subunits:  
97 S1 subunit responsible for binding between the virus and the receptor; and S2 subunit (C-  
98 terminal stem) that allows fusion of viral and cellular membranes. The S1 subunit is divided  
99 into an N-terminal domain (NTD) and a receptor binding domain (RBD) of the C-terminal  
100 region responsible for binding the virus to the host cell (ACE2) receptor binding domain [Lan  
101 2020] [Walls 2020]. The nucleocapsid (N protein) is involved in the packaging of RNA

102 during the externalization of viral particles from the infected cell and is an internal protein of  
103 the virus [Wang 2020]. The N protein appears more conserved across Betacoronavirus  
104 species than the S protein, while the RBD appears more conserved within the S1 unit. From  
105 the point of view of protection (i.e., neutralizing antibodies), there is a strong correlation  
106 between the levels of RBD antibodies and the neutralizing antibodies to SARS-CoV-2 in  
107 humans [Premkumar 2020]. Also, SARS-CoV-2 genome is closely related to SARS-CoV-1  
108 (79.6% genomic sequence identity), several antibodies covering all structural proteins of  
109 SARS-CoV-1 (spike, membrane, nucleocapsid, envelope) have been identified and  
110 extensively studied showing cross-reactivity with SARS-CoV-2, as well as partial cross-  
111 neutralization of spike antibodies [Bates 2020]. Moreover, sera from SARS-CoV-1  
112 convalescent or S1 CoV-specific animal antibodies can neutralize SARS-CoV-1 infection by  
113 reducing S protein-mediated SARS-CoV-1 entry [He 2006]. Finally, SARS-CoV-1 and  
114 MERS-CoV show that many fragments (S1-NTD, RBD, S2) of S protein are targets for  
115 neutralizing antibody production [He 2006] [Jiang 2020].

116

117 The objective of this present study was to identify a pre-existing natural humoral anti-SARS-  
118 CoV-2 immunity among population of African countries from sera repository collected  
119 several months before the COVID-19 epidemic started. Our work aimed to test the hypothesis  
120 of a previous exposure to a SARS-CoV-2 like antigens. We present here our first results,  
121 obtained from sera samples collected before January 2020 from people living in the  
122 Democratic Republic of Congo (DRC).

## 123 **MATERIAL AND METHODS**

124 **Antibody detection.** The INNOBIOCHIPS ELISA serological test used, detects the IgG  
125 antibodies targeting the N protein, the S1 protein, the RBD domain of the S1 protein, the  
126 NTD domain of the S1 protein and the S2 protein. The test values are obtained by optical  
127 density reading using a laser reader [INNOBIOCHIPS 2021]. The specificity of the test was  
128 evaluated using 25 samples positive for low pathogenic human coronaviruses (229E, OC43,  
129 NL63, HKU1) [John 2020]. All 25 samples tested negative for all SARS-CoV-2 proteins  
130 used in the ELISA test.

131 **Control sera collection.** The controls sera were obtained by INNOBIOCHIPS company from  
132 189 samples from blood donors collected in Northern France, randomly selected (EFS,  
133 Etablissement Français du Sang) and tested negative for SARS-CoV-2 by PCR. These sera

134 collection was used by the manufacturer to define the thresholds of positivity as compared to  
135 the sera collected from patients infected by SARS-CoV-2 (PCR test positive). We used this  
136 control group to establish thresholds for the absence of SARS-CoV-2-like antibodies with  
137 respect to their geographic origin while such blood donors are supposed to have not been in  
138 direct or indirect contact with bats. To eliminate the risk of false negatives (samples may  
139 come from donors of African or South Asian origin), for each antigen the distribution of  
140 control values was modeled. We used negative exponential distribution for the N, S2, RBD,  
141 NTD antigens and Weibull distribution for the S1 antigen (fig. 3) and we defined, for each  
142 antigen, the PRECOV threshold value corresponding to a probability equal to 0.0002. All  
143 control samples with a value for an antigen above the threshold will be considered as false  
144 negatives for this antigen. The results for the controls samples are shown in table 1. Among  
145 189 samples, we have 18 samples with at least 1 antigen above the PRECOV threshold: (9.5  
146 %), and 0 sample with at least 2 antigens above the threshold (0 %).


147 **Table 1.** Values of the INNOBIOCHIPS ELISA test for the controls, PRECOV threshold,  
148 and number of samples above the threshold.

Control (189 sera)	N	S1	S2	RBD	NTD
Min	0	0	0	0	0
Max	17.95	1.40	13.56	1.10	5.24
Mean	0.695	0.106	1.125	0.105	0.353
1 <sup>st</sup> quartile	0.07	0.04	0.08	0.02	0.03
Median	0.117	0.067	0.254	0.067	0.114
3 <sup>rd</sup> quartile	0.31	0.10	1.13	0.12	0.28
Standard Deviation	2.22	0.16	2.11	0.158	0.796
PRECOV threshold	9	0.6	10	0.6	4.5
Number of samples above threshold	3 (1.6 %)	4 (2.1 %)	3 (1.5 %)	5 (2.6 %)	3 (1.6 %)

149

150





151

152 Fig. 3: Control sample values distributions for the five tested antigens.

153 **Sample sera collection.** All 574 samples originated from two sources of sera collected from  
154 people living in the Democratic Republic of Congo including: The Monkole Hospital Center  
155 biobank (190 samples, collected in 2019); and the ALTADEVA/Monkole biobank (383  
156 samples, collected in 2014 and 2015). The sera from Monkole Hospital Center biobank  
157 samples were collected from healthy subjects among the hospital staff, from volunteers, and  
158 from young sickle-cell disease patients who are part of a study cohort. The sera, from the  
159 ALTADEVA biobank, were collected as part of a study of Plasmodium falciparum  
160 chemoresistance, conducted between March 2014 to December 2015 in the city-province of  
161 Kinshasa, in the central province of Kongo, and southwestern DRC. All samples were  
162 aliquoted and kept frozen as appropriate and each sample had companion data including date  
163 of collection, age, sex, and province of origin.

164 **Data analysis.** After calculating the statistical moments and the distribution of the samples'  
165 values for each antigen, several statistical tests and calculations were performed including:  
166 For each antigen, comparison of the means (Student's T-test) and the variances (F-test)  
167 between the samples group and the "control" group; Difference between the two groups  
168 (samples and controls) considering all the five antigens was tested using Hotelling test; The  
169 "control" group was taken as a whole, without excluding the few supposedly false-negative  
170 samples; Calculation of the number and percentage of samples considered positive for each  
171 antigen (with confidence interval), according to the cutoff value; calculation of the number of  
172 positive samples for two or more antigens.

173 **Ethical Approvals.** Consent for the study was obtained from all involved. All documents and  
174 samples were anonymized. Ethical approval was obtained from the Ethics Committee of the  
175 Centre de Formation et d'Appui Sanitaire/Centre Hospitalier Monkole (N/Ref:  
176 01/CEFAMONKOLE/CEL/2013). Blood samples were collected after obtaining informed  
177 consent, written in French and in the vernacular language used in Kinshasa and Central  
178 Kongo, from each patient or from his or her parent/guardian in the case of minors.

## 179 **RESULTS**

180 Antibodies against all five SARS-CoV-2 antigens were detected in the pre-COVID samples,  
181 with differential optical density mean value for DRC samples significantly higher than for the  
182 control samples, except for RBD antigen The S1 antigen shows the highest percentage of  
183 positives: 19.2% for DRC samples versus 2.11% for the control samples. The S2 antigen also  
184 shows high rate: 9.3% for DRC samples vs 1.6% for control samples (Table 2). The Hotelling  
185 test confirmed a high significant difference ( $T^2 = 35$ ,  $F = 7$ ,  $p\text{-value}=2.2*10^{-6}$ ) when all  
186 antigens were considered together.

187 **Table 2.** Democratic Republic of Congo study samples values (differential optical density).  
188 Caption: For each antigen, the table indicate the distribution of values and the number of  
189 samples with value above the PRECOV threshold (count, percentage and confidence interval  
190 of the percentage). The T-Test p-value indicate the probability of no difference between the  
191 mean of DRC samples and the mean of control samples.

192



DRC Samples (N= 574)	N	S1	S2	RBD	NTD
minimum	0	0	0	0	0
maximum	59.09	50.28	65.58	42.17	44.68
Mean	3.01	1.05	3.43	0.29	1.11
Standard deviation	7.72	4.32	7.90	1.85	3.76
1st quartile	0.16	0.088	0.196	0.000	0.047
Median	0.62	0.167	0.763	0.062	0.157
3rd quartile	1.92	0.396	2.852	0.182	0.578
Number of samples > PRECOV threshold (count, % and C.I.)	42 (7.3 % [5.2-9.5])	110 (19.2 %, [16.0-22.4])	45 (9.3 %) [7.1-11.5])	33 (5.7 %) [3.8-7.6])	32 (5.4 %) [3.6-7.2])
T-Test (Student)	p=3*10 <sup>-5</sup>	p=0.001	p=4*10 <sup>-5</sup>	p=0.08	p=0.003

193

194 Among the 574 samples, 201 samples reacted at least against 1 antigen above the threshold  
 195 (35% vs. 9.5% for the controls), while 50 samples reacted at least against 2 antigens above  
 196 the threshold (8.7% vs 0% for the controls).

## 197 **DISCUSSION**

198 Our results are in favor of the hypothesis that some populations in Africa and from other part  
 199 of the World might be less susceptible to the SARS-CoV2 infection due to a pre-existing  
 200 immunity triggered by other Betacoronavirus (alias Sarbecoviruses) of animal origin. Also,  
 201 higher serological cross-reactivity to SARS-CoV-2 in sub-Saharan African regions than in  
 202 the USA or elsewhere has already been reported and attributed to higher exposure to human  
 203 coronaviruses (HCoVs) [Mateus 2020]. Although, the hypothesis that infection with other  
 204 Coronaviruses can induce a consistent level of pre-existing immunity against SARS-CoV2  
 205 has been reported for T cells [Le Bert 2020], this is the first time that specific antibodies  
 206 against SARS-CoV2 proteins in sera collected before the SARS-CoV-2 emergence in China  
 207 has been reported in Central Africa. Moreover, it has been showed that cross-reactive T cells  
 208 against SARS-CoV2 can be induced by Common Cold Coronavirus, SARS-CoV1 or  
 209 eventually other animal betacoronaviruses [Mateus 2020] [Braun 2020] [Le Bert 2020].  
 210 Contrary to what was published by Tso et al. [Tso 2020], the specificity of the test used in  
 211 this work excludes reactions against congenital human coronaviruses (e.g. HCoV-NL63,

212 HCoV-229E) and confirms that the identified antibodies react precisely against the SARS-  
213 Cov-2 proteins. The novelty of our finding is that a stronger cross-reactivity in central  
214 African regions may come from exposure, not to HCoVs, but to other animal coronaviruses  
215 or more specifically ones associated to chiropteran. Also, several betacoronaviruses have  
216 been found in horseshoe bats, as well as specific antibody response to these viruses in fruit  
217 bats in Africa [Nziza 2020] [Müller 2007].

218 Based on what we observed that cross-reactivity to S1 and S2, considered specific to SARS-  
219 CoV-2, was stronger than for the N protein, considered common to beta-coronaviruses,  
220 therefore, it can be assumed that cross-reactivity to S1 and S2 must have been induced by a  
221 virus similar – by this spike epitopes – to SARS-CoV-2, rather than by other known human  
222 betacoronaviruses. Indeed, The S1 subunit is the least conserved and cross-reactivity cannot  
223 be explained by exposure to the known Human CoVs while the N and S2 proteins are the  
224 most conserved. Moreover, such cross-reactivity with S1 does not quantitatively reproduced  
225 the S1-RBD or S1-NTD data. These apparent discrepancies can be explained by a variation  
226 of antibodies affinities to these epitopes due to the structure of the spike or due to a change in  
227 their amino acid sequence. Eventually a more consistent response with S1 could be the fact of  
228 a non-tested here CTD protein [Van Elslande 2020]. Altogether such apparent discrepancy of  
229 antibody response is in favor of an S1 belonging to a Sars-Cov2-like, while all sequence of  
230 the antigens included in the commercial ELISA (INNOBIOCHIPS) were entirely based on  
231 the reference SARS-CoV-2 strain. It is also important to note that S and N protein sequences  
232 are equally divergent among coronaviruses while the S2 subunit is better conserved than the  
233 N protein.

234 We are aware of the limitations of this somewhat pioneering study. The next step is to  
235 conduct sensitive investigations of populations potentially exposed to wild animals and to  
236 perform back-to-back with the present ELISA test, an essential SARS-Cov-2 neutralization  
237 assays to confirm the surprisingly high S1 cross-reactivity and the potential of the antibody to  
238 protect against SARS-CoV-2. In addition, most of the samples tested came from rural areas  
239 of Central Congo (e.g.: Kimpese of Lower Congo, Kisantu of Western Congo). Furthermore,  
240 if it is true that background reactivity in SARS-CoV-2 serological tests is higher, especially  
241 in African populations, this may be due not only to widespread circulation/exposure of/to  
242 Sarbecoviruses (alias Betacoronavirus) of animals or chiropterans, but to a potential increased  
243 cross-reactivity induced by other microorganisms (e.g., malaria, tuberculosis, etc.) as  
244 previously observed [Ng 2020] [Stettler 2016] [Welsh 2010].

245 **CONCLUSION**

246 In conclusion, our study strongly suggests that a SARS-CoV-2-like virus circulated in the  
247 Central African sub-region before the pandemic, inducing a cross immunity and eventual  
248 cross-protection in the local population. Given the now well-established phylogeny of  
249 Betacoronavirus, it is likely that this not yet identified virus could be associated with  
250 chiropteran species. Our study is underway in other African and Asian countries, as well as  
251 evaluating the neutralizing potential of these pre-pandemic SARS-CoV-2 antibodies.

252

## 253 **REFERENCES**

- 254 [Bates 2020] Bates TA, Weinstein JB, Farley S, Leier HC, Messer WB, Tafesse FG. Cross-  
255 reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2, *Cell Reports*  
256 (2021).
- 257 [Bequart 2010] Becquart P, Wauquier N, Mahlaköiv T, et al. High prevalence of both  
258 humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. *PLoS*  
259 *One*. 5(2):e9126 (2010).
- 260 [Braun 2020] Braun J., Loyal L., Frensch M. et al. SARS-CoV-2-reactive T cells in healthy  
261 donors and patients with COVID-19. *Nature* 587, 270–274 (2020)
- 262 [Dos Santos Franco 2019] Dos Santos Franco L, Gushi LT, Luiz WB, Amorim JH. Seeking  
263 Flavivirus Cross-Protective Immunity. *Front Immunol*. 10:2260 (2019).
- 264 [Gonzalez 2000] Gonzalez JP, Nakoune E, Slenczka W, Vidal P, Morvan JM. Ebola and  
265 Marburg virus antibody prevalence in selected populations of the Central African Republic.  
266 *Microbes Infect*. 2:39–44 (2000).
- 267 [He 2006] He Y. et al. Cross-neutralization of human and palm civet severe acute respiratory  
268 syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.  
269 *J. Immunol*. 176, 6085–6092 (2006).
- 270 [Hu 2017] Hu B, Zeng LP, Yang XL, et all. Discovery of a rich gene pool of bat SARS-  
271 related coronaviruses provides new insights into the origin of SARS coronavirus. *PLoS*  
272 *Pathog*. 13(11):e1006698 (2017).
- 273 [Hul 2021] Vibol Hul, Deborah Delaune, et al. A novel SARS-CoV-2 related coronavirus in  
274 bats from Cambodia. *bioRxiv* 2021.01.26.428212; doi:  
275 <https://doi.org/10.1101/2021.01.26.428212>
- 276 [INNOBIOCHIPS 2021] INNOBIOCHIPS. Information for Use CoViDiag: Version 1.3.  
277 Available online: [https://www.innobiochips.fr/ applications/covidiag](https://www.innobiochips.fr/applications/covidiag) (accessed on 14  
278 February 2021).
- 279 [Jiang 2020] Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and  
280 Other Human Coronaviruses. *Trends Immunol*. 41(5):355-359 (2020). Erratum in: *Trends*  
281 *Immunol*. 2020 Apr 24;

- 282 [John 2020] John M.K., Loh T.P. et al. IFCC interim guidelines on serological testing of  
283 antibodies against SARS-CoV-2. *Clin. Chem. Lab. Med.* 2020.
- 284 [Kingdom 2013] Kingdom J, Happold D, Butynski T, Hoffmann M, Happold M, Kalina J.  
285 Mammals of Africa, Vol. 4. Bloomsbury Publishing, 2013.
- 286 [Lan 2020] Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding  
287 domain bound to the ACE2 receptor. *Nature* 2020, 581, 215–220.
- 288 [Le Bert 2020] Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell  
289 immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature*. 2020  
290 Aug;584(7821):457-462.
- 291 [Li 2005] Li W, Shi Z, Yu M, et al. Bats are natural reservoirs of SARS-like coronaviruses.  
292 *Science*. 2005 Oct 28;310(5748):676-9.
- 293 [Mallapaty 2020] Mallapaty S. Coronaviruses closely related to the pandemic virus  
294 discovered in Japan and Cambodia. *Nature*. 2020 Dec;588(7836):15-16.
- 295 [Mateus 2020] Mateus J, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in  
296 unexposed humans. *Science* 2020; 370: 89-94.
- 297 [Müller 2007] Müller MA, Paweska JT, Leman PA, et al. Coronavirus antibodies in African  
298 bat species. *Emerg Infect Dis*. 2007;13(9):1367-1370.
- 299 [Ng 2020] Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral  
300 immunity to SARS-CoV-2 in humans. *Science*. 2020 Dec 11;370(6522):1339-1343.
- 301 [Nziza 2020] Nziza J, Goldstein T, Cranfield M, et al. Coronaviruses Detected in Bats in  
302 Close Contact with Humans in Rwanda. *EcoHealth* 17, 152–159 (2020).  
303 <https://doi.org/10.1007/s10393-019-01458-8>
- 304 [Premkumar 2020] Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding  
305 domain of the viral spike protein is an immunodominant and highly specific target of  
306 antibodies in SARS-CoV-2 patients. *Sci. Immunol.* 2020, 5.
- 307 [Stettler 2016] Stettler K, Beltramello M, Espinosa DA, et al. Specificity, cross-reactivity,  
308 and function of antibodies elicited by Zika virus infection. *Science*. 2016 Aug  
309 19;353(6301):823-6.

- 310 [Tso 2020] Tso FY, Lidenge SJ, Peña PB, Clegg AA, et al. High prevalence of pre-existing  
311 serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-  
312 CoV-2) in sub-Saharan Africa. *Int J Infect Dis.* 2021 Jan;102:577-583.
- 313 [Van Elslande 2020] Van Elslande, J, Decru, B, Jonckheere, S., et al. Antibody response  
314 against SARS-CoV-2 spike protein and nucleoprotein evaluated by four automated  
315 immunoassays and three ELISAs. *Clin. Microbiol. Infect.* 2020.
- 316 [Walls 2020] Walls AC, Park YJ, Tortorici, MA, et al. Structure, Function, and Antigenicity  
317 of the SARS-CoV-2 Spike Glycoprotein. *Cell* 2020, *181*, 281–292.
- 318 [Wang 2020] Wang MY, Zhao R, Gao LJ, et al. SARS-CoV-2: Structure, Biology, and  
319 Structure-Based Therapeutics Development. *Front Cell Infect Microbiol.* 2020 Nov  
320 25;10:587269.
- 321 [Welsh 2010] Welsh RM, Che JW, Brehm MA, Selin LK. Heterologous immunity between  
322 viruses. *Immunol Rev.* 2010 May;235(1):244-66.
- 323 [WHO 2021] WHO Coronavirus Disease Dashboard. <https://covid19.who.int/> (last visited  
324 Apr.26, 2021).
- 325 [Zhou 2020] Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a  
326 new coronavirus of probable bat origin. *Nature.* 2020 Mar;579(7798):270-273.